Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 5Breast 5Gastrointestinal 4Genitourinary 2Dermatologic 2

Conditions

Melanoma 2Neoplasms 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 194aldesleukin 145Interleukin-2 109fludarabine phosphate 107Temozolomide 83fludarabine 81Dacarbazine 81Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Magnetic Resonance Spectroscopy 48Carboplatin 48Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42Specimen Handling 42atezolizumab 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × tesetaxel × Dermatologic × Clear all
NCT01064713 2018-07-17

Phase II Study of Tesetaxel in Metastatic Melanoma

M.D. Anderson Cancer Center

Phase 2 Completed
17 enrolled 5 charts
Dermatologic

Melanoma, Neoplasms

NCT01092585 2011-11-08

Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH

Genta Incorporated

Phase 2 Unknown
27 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡